TRNS

Transcat is a high-quality niche compounder whose underlying business is working — the MD&A flags the 68th consecutive quarter of year-over-year Service-segment growth, Service revenue up 19.7% and Distribution up 18.2% in FY2026, with total revenue jumping 19.2% to $332M. Distribution gross margin actually expanded 320 bps on better rental mix, and total gross profit rose 21.1% to $108M (32.6% margin). This is a recurring-revenue calibration franchise serving regulated end-markets, and the long-horizon strategy of bolt-on M&A (Essco, Martin contributed $30.9M of acquired revenue) is intact.

The problem is below the gross line. Net income collapsed -63.0% to $5.38M and diluted EPS fell to $0.57, driving the trailing P/E to a punishing 160.9x at $91.70. The MD&A admits Service gross margin slipped 90 bps on 'costs associated with new customer wins and lower than expected levels of organic growth in the first half', and the income statement walk shows G&A expense ratio jumping from 13.7% to 15.8% and interest/other flipping from +0.2% income to -1.6% expense. That interest swing ties directly to the balance sheet: long-term debt ballooned +223.3% to $99.9M to fund the deals, total liabilities are up 82.9%, and D&A is up 41.0% to $26.2M — acquisition accounting is eating reported earnings.